Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
NCT ID: NCT05405244 Phase: PHASE3 Status: COMPLETED Enrollment: 55 Completion: 2019-09-19
Conditions
Overweight and Obesity, Eating Behavior
Interventions
Placebo, Bromocriptine-QR
Summary
The current project applies an integrative three-prong approach to investigate the potential of the dopamine D2 receptor (DRD2) agonist bromocriptine to: 1) increase homeostatic satiation signaling, 2) alter neural circuitry to reduce hedonically motivated food intake, and 3) examines a genetic predisposition that may markedly impact the effectiveness of this medication in those at high risk for T2DM.
Primary Outcome
Ad Libitum Food and Beverage Intake (g)